GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Cash Payments for Deposits by Banks and Customers

Biogen (MEX:BIIB) Cash Payments for Deposits by Banks and Customers


View and export this data going back to 2013. Start your Free Trial

What is Biogen Cash Payments for Deposits by Banks and Customers?

Cash Payments for Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


Biogen (MEX:BIIB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Cash Payments for Deposits by Banks and Customers
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.